沈迎,王伟民,张奇,周玉杰,沈卫峰

• 1:上海交通大学医学院附属瑞金医院心脏科
• 2:北京大学人民医院心内科
• 3:同济大学上海市东方医院心内科
• 4:首都医科大学附属北京安贞医院心内科

摘要(Abstract)：

近年来，我国的经皮冠状动脉介入治疗（PCI）规范化管理取得了很大进步。胸痛中心建设无疑是ST段抬高型心肌梗死的一种非常有效的救治模式。对非ST段抬高型急性冠状动脉综合征患者在入院时进行危险分层是合理应用介入策略和改善临床预后的前提。PCI已广泛用于高危患者（高龄、急性冠状动脉综合征、心力衰竭或内科合并症等）和各种复杂冠状动脉病变（左主干、冠状动脉慢性完全闭塞、严重钙化等）的治疗，并可达到与冠状动脉旁路移植术相同的临床疗效。冠状动脉内影像和功能学评估的应用，使更多的冠状动脉病变获得更精准的介入治疗。介入操作技能的改进和新技术的开展，以及术后抗血小板的正确使用，显著提高了特殊复杂病变PCI的成功率和远期疗效。本文对2022年PCI临床研究进展做一简要的回顾。

关键词(KeyWords)： 经皮冠状动脉介入治疗;急性/慢性冠状动脉综合征;指南/专家共识;血管内影像/功能学评估;抗血小板治疗

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 沈迎,王伟民,张奇,周玉杰,沈卫峰

参考文献(References)：

• [1] Alkhalil M. An overview of current advances in comtemporary percutaneous coronary intervention[J]. Curr Cardiol Rev,2022,18(1):e150322202194. DOI:10.2174/1573403X1801220315090538.
• [2]马丽媛，王增武，樊静，等.《中国心血管健康与疾病报告2021》概要[J].中国介入心脏病学杂志，2022,30(7):481-496.DOI:10.3969/j.issn.1004-8812.2022.07.001.
• [3] Kawashima H, Serruys PW, Hara H, et al. 10-year all-cause mortality following percutaneous or surgicl revascularization in patients with heavy calcification[J]. JACC Cardiovasc Interv,2022, 15(2):193-204. DOI:10.1016/j.jcin.2021.10.026.
• [4] Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization:a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines[J]. Circulation,2022,145(3):e18-e114. DOI:10.1161/CIR.0000000000001038.
• [5] Collet JP, Thiele H, Barbato E, et al. 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation[J]. Eur Heart J, 2021, 42(14):1289-1367. DOI:10.1093/eurheartj/ehaa575.
• [6]中华医学会心血管病学分会介入心脏病学组，中国医师协会心血管内科医师分会血栓防治专业委员会，中华心血管病杂志编辑委员会.中国经皮冠状动脉介入治疗指南（2016）[J].中华心血管病杂志，2016,44(5):382-400. DOI:10.3760/cma.j.issn.0253-3758.2016.05.006.
• [7] Knuuti J, Wijns W, Saraste A, et al. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes[J]. Eur Heart J, 2020, 41(3):407-477. DOI:10.1093/eurheartj/ehz425.
• [8]李琪，王伟民，刘健，等.冠状动脉介入治疗对不稳定型心绞痛患者心功能和中长期预后的影响[J].中国介入心脏病学杂志，2022,30(9):672-677. DOI:10.3969/j.issn.1004-8812.2022.09.006.
• [9] Damluji AA, Forman DE, Wang TY, et al. American Heart Association cardiovascular disease in older populations committee of the council on clinical cardiology and council on cardiovascular and stroke nursing; council on cardiovascular radiology and intervention;and council on lifestyle and cardiometabolic health.management of acute coronary syndrome in the older adult population:a scientific statement from the American Heart Association[J]. Circulation,2023, 147(3):e32-e62. DOI:10.1161/CIR.0000000000001112.
• [10]复杂冠心病血运重建心脏团队决策研究协作组.复杂冠心病血运重建策略内外科专家共识[J].中国循环杂志，2022, 37(11):1073-1085. DOI:10.3969/j.issn.1000-3614.2022.11.001.
• [11] Kontos MC, de Lemos JA, Deitelzweig SB, et al. 2022 ACC expert consensus decision pathway on the evaluation and disposition of acute chest pain in the emergency department:a report of the American College of Cardiology solution set oversight committee[J]. J Am Coll Cardiol, 2022, 80(20):1925-1960. DOI:10.1016/j.jacc.2022.08.750.
• [12]中国胸痛中心联盟，中国心血管健康联盟，苏州工业园区心血管健康研究院，等.《中国胸痛中心质控报告（2021）》概要[J].中国介入心脏病学杂志，2022, 30(5):321-327. DOI:10.3969/j.issn.1004-8812.2022.05.001.
• [13]霍勇.中国胸痛中心建设理论与医学模式[J].中国介入心脏病学杂志，2021, 29(1):1-3. DOI:10.3969/j.issn.1004-8812.2021.01.001.
• [14]霍勇.从胸痛中心到新型心血管疾病防治体系建设[J].中国介入心脏病学杂志，2021, 29(3):124-126. DOI:10.3969/j.issn.1004-8812.2021.03.002.
• [15]国家卫生健康委医政医管局.国家卫生健康委办公厅关于印发2022年国家医疗质量安全改进目标的通知-提高非ST段抬高型急性冠脉综合征患者接受危险分层的百分比[J/OL].(2022-03-01)[2023-01-18].http：//www.nhc.gov.cn/yzygj/s3585/202203/ff ed3474b1884058841a07c144ad094e.shtml.
• [16] Parikh PB, Bhatt DL, Bhasin V, et al. Impact of percutaneous coronary intervention on outcomes in patients with heart failure.JACC State-of-the-Art Review[J]. J Am Coll Cardiol, 2021, 77(19):2432-2447. DOI:10.1016/j.jacc.2021.03.310.
• [17]中华医学会心血管病学分会，中华心血管病杂志编辑委员会.急性心肌梗死合并心原性休克诊断和治疗中国专家共识（2021）[J].中华心血管病杂志，2022, 50(3):231-242. DOI:10.3760/cma.j.cn112148-20210706-00574.
• [18]游洁芸，耿立，沈运丽，等.脉搏指数连续心排血量监测改善急性心肌梗死合并心原性休克患者临床预后研究[J].中国介入心脏病学杂志，2022, 30(9):665-671. DOI:10.3969/j.issn.1004-8812.2022.09.005.
• [19]沈迎，丁风华，张瑞岩，等.优化左心室收缩功能减退患者冠状动脉血运重建策略[J].中国介入心脏病学杂志，2022, 30(9):641-643. DOI:10.3969/j.issn.1004-8812.2022.09.001.
• [20] Perera D, Clayton T, O’Kane PD, et al. Percutaneous revascularization for ischemic left ventricular dysfunction[J].N Engl J Med, 2022, 387(15):1351-1360. DOI:10.1056/NEJMoa2206606.
• [21] Sun LY, Gaudino M, Chen RJ, et al. Long-term outcomes in patients with severely reduced left ventricular ejection fraction undergoing percutaneous coronary intervention vs. coronary artery bypass grafting[J]. JAMA Cardiol, 2020, 5(6):631-641. DOI:10.1001/jamacardio.2020.0239.
• [22] Park S, Ahn JM, Kim TO, et al. Revascularization in patients with lef t main coronary artery disease and lef t ventricular dysfunction[J]. J Am Coll Cardiol, 2020, 76(12):1395-1406.DOI:10.1016/j.jacc.2020.07.047.
• [23] Thuijs D, Miojevic M, Stone GW, et al. Impact of left ventricular ejection fraction on clinical outcomes after left main coronary artery revascularization:results from the randomized EXCEL trial[J]. Eur J Heart Fail, 2020, 22(5):871-879. DOI:10.1002/ejhf.1681.
• [24] Brophy TJ, Warsavage TJ, Hebbe AL, et al. Percutaneous coronary intervention in patients with stable coronary artery disease and left ventricular systolic dysfunction:insights from the VA CART program[J].Am Heart J, 2021, 235:149-157. DOI:10.1016/j.ahj.2021.02.002.
• [25]廉坤，谢炜巍，陈根锐，等.体外膜肺氧合联合主动脉内球囊反搏辅助下行择期经皮冠状动脉介入治疗对复杂高危冠心病的中期疗效[J].中国介入心脏病学杂志，2021, 29(7):380-385. DOI:10.3969/j.issn.1004-8812.2021.07.004.
• [26]中华医学会心血管病学分会，中华心血管病杂志编辑委员会.中国冠状动脉左主干分叉病变介入治疗指南[J].中华心血管病杂志，2022, 50(4):349-360. DOI:10.3760/cma.j.cn112148-20211010-00870.
• [27]沈卫峰，丁风华，张瑞岩.冠状动脉腔内影像学指导左主干病变介入治疗[J].中国介入心脏病学杂志，2021, 29(9):481-483. DOI:10.3969/j.issn.1004-8812.2021.09.001.
• [28] Azzalini L, Karmpaliotis D, Santiago R, et al. Contemporary issue in chronic total occlusion percutaneous coronary intervention[J]. J Am Coll Cardiol, 2022, 15(1):1-21. DOI:10.1016/j.jcin.2021.09.027.
• [29]沈迎，全进伟，杨晨蝶，等.冠状动脉侧支循环对冠状动脉慢性闭塞病变伴心力衰竭患者介入治疗后左心功能的影响[J].中国介入心脏病学杂志，2022, 30(9):653-659. DOI:10.3969/j.issn.1004-8812.2022.09.003.
• [30] Ybarra LF, Rinfret S, Brilakis ES, et al. Defi nitions and clinical trial design principles for coronary artery chronic total occlusion therapies:CTO-ARC Consensus Recommendations[J]. Circulation, 2021, 143(5):479-500. DOI:10.1161/CIRCULATIONAHA.120.046754.
• [31] Wu EB, Brilakis ES, Mashayekhi K, et al. Global chronic total occlusion crossing algorithm:JACC State-of-the-art review[J]. J Am Coll Cardiol, 2021, 78(8):840-853. DOI:10.1016/j.jacc.2021.05.055.
• [32]葛均波，葛雷，霍勇，等.中国冠状动脉慢性完全闭塞病变介入治疗推荐路径更新[J].中国介入心脏病学杂志，2021, 29(6):302-305. DOI:10.3969/j.issn.1004-8812.2021.06.002.
• [33] Hong SJ, Kim BK, Cho I, et al. CT-CTO Investigators.Ef f ect of coronary CTA on chronic total occlusion percutaneous coronary intervention:a randomized trial[J]. JACC Cardiovasc Imaging, 2021, 14(10):1993-2004. DOI:10.1016/j.jcmg.2021.04.013.
• [34]聂文畅，刘健. 2 0 21年冠状动脉腔内影像学进展[J].中国介入心脏病学杂志，2022, 30(8):622-625. DOI:10.3969/j.issn.1004-8812.2022.08.010.
• [35]宋雷，张晗，杨跃进.血管内超声在慢性完全闭塞病变介入治疗中的价值[J].中国介入心脏病学杂志，2021, 29(9):515-519. DOI:10.3969/j.issn.1004-8812.2021.09.007.
• [36]《冠状动脉钙化病变诊治中国专家共识》专家组.冠状动脉钙化病变诊治中国专家共识（2021版）[J].中国介入心脏病学杂志，2021, 29(5):241-250. DOI:10.3969/j.issn.1004-8812.2021.05.002.
• [37] Redfors B, Sharma SK, Saito S, et al. Novel micro crown orbital atherectomy for severe lesion calcifi cation:coronary orbital atherectomy system study(COAST)[J]. Circ Cardiovasc Interv, 2020, 13(8):e008993. DOI:10.1161/CIRCINTERVENTIONS.120.008993.
• [38]滕玮利，曹成富，李琪，等.冠状动脉斑块旋磨术治疗严重钙化病变的临床结果及影响因素分析[J].中国介入心脏病学杂志，2021,29(11):601-606. DOI:10.3969/j.issn.1004-8812.2021.11.001.
• [39]梁会珠，马玉良，李琪，等.冠状动脉斑块旋磨术治疗冠状动脉弥漫钙化病变的长期安全性及有效性[J].中国介入心脏病学杂志，2022, 30(11):814-818. DOI:10.3969/j.issn.1004-8812.2022.11.003.
• [40]王菁，马墩亮，钟志安，等.评价血管内冲击波碎石术在小型猪冠状动脉中应用的安全性[J].中国介入心脏病学杂志，2022, 30(8):606-612. DOI:10.3969/j.issn.1004-8812.2022.08.008.
• [41] Karimi Galougahi K, Shlofmitz E, Jeremias A, et al. Therapeutic approach to calcifi ed coronary lesions:disruptive technologies[J]. Curr Cardiol Rep, 2021, 23(4):33. DOI:10.1007/s11886-021-01458-7.
• [42] Kereiakes DJ, Di Mario C, Riley RF, et al. Intravascular lithotripsy for treatment of calcified coronary lesions:patient-level pooled analysis of the Disrupt CAD Studies[J]. JACC Cardiovasc Interv,2021, 14(12):1337-1348. DOI:10.1016/j.jcin.2021.04.015.
• [43]折振兴，于波.易损斑块成像进展[J].中国介入心脏病学杂志，2022, 30(3):208-213. DOI:10.3969/j.issn.1004-8812.2022.03.009.
• [44] Kinnaird T, Johnson T, Anderson R, et. al. Intravascular imaging and 12-month mortality after unprotected left main stem PCI:an analysis from the British Cardiovascular Intervention Society database[J]. JACC Cardiovasc Interv, 2020, 13(3):346-357.DOI:10.1016/j.jcin.2019.10.007.
• [45]王思琦，李琪，滕伟利，等.冠状动脉血管内超声对严重钙化病变斑块旋磨术终点判断的评价研究[J].中国介入心脏病学杂志，2021, 29(9):490-494. DOI:10.3969/j.issn.1004-8812.2021.09.003.
• [46] Parikh RV, Fearon WF. Physiology over angiography to determine lesion severity:the FAME trials[J]. Interv Cardiol Clin, 2020, 9(4):409-418. DOI:10.1016/j.iccl.2020.05.001.
• [47] Fearon WF, Zimmermann FM, De Bruyne B, et al. Fractional fl ow reserve-guided PCI as compared with coronary bypass surgery[J]. N Engl J Med, 2022, 386(2):128-137. DOI:10.1056/NEJMoa2112299.
• [48]沈迎，丁风华，张瑞岩，等.冠状动脉狭窄功能学评估临床展望[J].中国介入心脏病学杂志，2021, 29(3):121-123. DOI:10 .3969/j.issn.1004-8812.2021.03.001.
• [49]余作忠，杨人强.基于影像学的血流储备分数衍生指标研究进展[J].中国介入心脏病学杂志，2021, 29(3):164-168. DOI:10.3969/j.issn.1004-8812.2021.03.010.
• [50] Xu B, Tu SX, Song L, et al. Angiographic quantitative fl ow ratioguided coronary intervention(FAVORⅢChina):a multicentre,randomised, sham-controlled trial[J]. Lancet, 2021, 398(10317):2149-2159. DOI:10.1016/S0140-6736(21)02248-0.
• [51] Koo BK, Hu X, Kang J, et al. Fractional flow reserve or intravascular ultrasonography to guide PCI[J]. N Engl J Med,2022, 387(9):779-789. DOI:10.1056/NEJMoa2201546.
• [52] Burzotta F, Leone AM, Aurigemma C, et al. Fractional flow reserve or optical coherence tomography to guide management of angiographically intermediate coronary stenosis:a single-center trial[J]. JACC Cardiovasc Interv, 2020, 13(1):49-58. DOI:10.1016/j.jcin.2019.09.034.
• [53] Kedhi E, Berta B, Roleder T, et al. Thin-cap fi broatheroma predicts clinical events in diabetic patients with normal fractional flow reserve:the COMBINE OCT-FFR trial[J]. Eur Heart J, 2021, 42(45):4671-4679. DOI:10.1093/eurheartj/ehab433.
• [54] Fabris E, Berta B, Roleder T, et al. Thin-cap fi broatheroma rather than any lipid plaques increases the risk of cardiovascular events in diabetic patients:insights from the COMBINE OCT-FFR trial[J].Circ Cardiovasc Interv, 2022, 15(5):e011728. DOI:10.1161/CIRCINTERVENTIONS.121.011728.
• [55] Giacoppo D, Matsuda Y, Fovino LN, et al. Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents:a systematic review and metaanalysis of randomized clinical trials[J]. Eur Heart J, 2021, 42(4):308-319. DOI:10.1093/eurheartj/ehaa739.
• [56]韩亚玲，李岩.经皮冠状动脉介入治疗后优化抗血小板治疗进展2021[J].中华心血管病杂志，2021, 49(12):1184-1186. DOI:10.3760/cma.j.cn112148-20211027-00919.
• [57] Zhou X, Angiolillo DJ, Ortega-Paz L. P2Y12 inhibitor monotherapy after percutaneous coronary intervention[J]. J Cardiovasc Dev Dis,2022, 9(10):340. DOI:10.3390/jcdd9100340.
• [58] Capodanno D, Baber U, Bhatt DL, et al. P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention[J]. Nat Rev Cardiol, 2022, 19(12):829-844. DOI:10.1038/s41569-022-00725-6.
• [59] Escaned J, Cao D, Baber U, et al. Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention:TWILIGHT-HBR[J]. Eur Heart J, 2021, 42(45):4624-4634. DOI:10.1093/eurheartj/ehab702.
• [60] Valgimigli M, Cao D, Angiolillo DJ, et al. Duration of dual antiplatelet therapy for patients at high bleeding risk undergoing PCI[J]. JACC, 2021, 78(21):2060-2072. DOI:10.1016/j.jacc.2021.08.074.
• [61] Capodanno D, Bhatt DL, Gibson M, et al. Bleeding avoidance strategies in percutaneous coronary intervention[J]. Nat Rev Cardiol, 2022, 19(2):117-132. DOI:10.1038/s41569-021-00598-1.
• [62] Matsuura Y, Moribayashi K, Kaikita K. Optimal antithrombotic therapy in patients undergoing percutaneous coronary intervention:a focused review on high bleeding risk[J]. J Atheroscler Thromb,2022, 29(10):1409-1420. DOI:10.5551/jat.RV17066.
• [63] Yamamoto K, Shiomi H, Morimoto T, et al. Ischemic and bleeding risk after complex percutaneous coronary intervention in patients with or without high bleeding risk[J]. Catheter Cardiovasc Interv,2021, 97(6):E758-E770. DOI:10.1002/ccd.29335.
• [64] Zhao X, Li J, Liu F, et al. The PRECISE-DAPT score and 5-year outcomes after percutaneous coronary intervention:a large-scale,real-world study from China[J]. Eur Heart J Qual Care Clin Outcomes, 2022, 8(8):812-820. DOI:10.1093/ehjqcco/qcab068.
• [65] Boudreau R, Fu AYN, Barry QS, et al. Outcomes in patients stratifi ed by PRECISE-DAPT versus DAPT scores after percutaneous coronary interventions[J]. Am J Cardiol, 2021, 161:19-25. DOI:10.1016/j.amjcard.2021.08.055.
• [66] Na K, Qiu M, Ma S, et al. Impact of ticagrelor vs. clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention after risk stratification with the CHA2DS2-VASc score[J]. Front Cardiovasc Med, 2022, 9:808571. DOI:10.3389/fcvm.2022.808571.
• [67] Galli M, Benenati S, Capodanno D, et al. Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention:a systematic review and meta-analysis[J]. Lancet, 2021,397(10283):1470-1483. DOI:10.1016/S0140-6736(21)00533-X.
• [68] Jeong MH, Chavez I, Gordon P, et al. Eff ect of genotype guided oral P2Y12 inhibitor selection vs. conventional clopidogrel therapy on ischemic outcomes after percutaneous coronary intervention:the TAILOR-PCI randomized clinical trial[J]. JAMA, 2020, 324:761-771. DOI:10.1001/jama.2020.12443.
• [69] van der Sangen NMR, Rozemeijer R, Yin CP, et al. Patient-tailored antithrombotic therapy following percutaneous coronary intervention[J]. Eur Heart J, 2021, 42(10):1038-1046. DOI:10.1093/eurheartj/ehaa1097.
• [70] Capodanno D, Angiolillo DJ, Lennon RJ, et al. ABCD-GENE score and clinical outcomes following percutaneous coronary intervention:Insights from the TAILOR-PCI trial[J]. J Am Heart Assoc, 2022,11(4):e024156. DOI:10.1161/JAHA.121.024156.
• [71] Thomas CD, Franchi F, Keeley EC, et al. Impact of the ABCDGENE score on clopidogrel clinical eff ectiveness after PCI:a multisite, real-world investigation[J]. Clin Pharmacol Ther, 2022, 112(1):146-155. DOI:10.1002/cpt.2612.
• [72] Saito Y, Nishi T, Wakabayashi S, et al.Validation of the ABCDGENE score to identify high platelet reactivity in east Asian patients undergoing percutaneous coronary intervention[J]. Int J Cardiol,2021, 327:15-18. DOI:10.1016/j.ijcard.2020.11.022.
• [73]刘耀琨，郑博，陈楚云，等.中国县域医院心血管专科冠状动脉复杂病变介入治疗能力现状——基于2021年304家县级医院的调研[J].中国介入心脏病学杂志，2022, 30(8):596-600. DOI:10.3969/j.issn.1004-8812.2022.08.006.
• [74]张鸿，王梓凝，李怀勤，等.围术期抗血栓药物使用情况调查[J].中国介入心脏病学杂志，2022, 30(1):23-28. DOI:10.3969/j.issn.1004-8812.2022.01.004.
• [75] Patterson T, Clayton T, Dodd M, et al. ACTIVATION(percutaneous coronary intervention prior to transcatheter aortic valve implantation):a randomized clinical trial[J]. JACC Cardiovasc Interv, 2021, 14(18):1965-1974. DOI:10.1016/j.jcin.2021.06.041.
• [76]李蕾，董淑杰，乔蕊，等.抗栓新模式——多学科协作[J].中国介入心脏病学杂志，2022, 30(4):303-307. DOI:10.3969/j.issn.1004-8812.2022.04.010.
• [77]沈雳，李晨光，吴轶喆，等.《中国心血管医疗器械产业创新白皮书（2021）》概要[J].中国介入心脏病学杂志，2022, 30(4):251-258. DOI:10.3969/j.issn.1004-8812.2022.04.002.